Defining neuropsychiatric symptoms fluctuations in Parkinson’s disease
Objective: To evaluate the demographic and clinical correlates of Parkinson’s disease (PD) patients with fluctuations of neuropsychiatric symptoms (NPS-F). Background: Clinical correlates of fluctuations of…Cognitive underside of Parkinson’s Disease: A working memory updating failure in freezing of gait
Objective: To investigate the role of components of working memory updating in freezing of gait phenomenon Parkinson’s Disease Background: The role of cognitive deficits has…Coping strategies in people with Parkinson disease (PwP)
Objective: To compare how PwP coped in two situations along their lives: (a) Parkinson disease diagnosis and (b) COVID-19 pandemic, and how their environment played…Prediction of turning characteristics parameters into Parkinson’s disease
Objective: To investigate the parameters predicting turning dysfunction in individuals with Parkinson’s disease (PD). Background: Turning deficit in PD has significant implications particularly regarding increase…Apolipoprotein E e4 genotype affects early motor progression in Parkinson’s disease through an effect on cognition
Objective: To evaluate the relationship between APOE e4 genotype, cognition, and motor progression in early Parkinson’s disease (PD). Background: The Apolipoprotein E (APOE) e4 genotype…Chronic pain and the polytrauma clinical triad are risk factors for prodromal PD
Objective: This study aimed to assess whether chronic pain is a risk factor for prodromal Parkinson disease and determine if pain severity and comorbidity with…Can a single-session of weight-shift training support people with Parkinson’s step from a freeze?
Objective: To assess the efficacy and the safety of a weight-shift (WS) intervention used in a complex and demanding gait context Background: Freezing of gait…Drivers of longitudinal healthcare cost in Parkinson Disease
Objective: To identify associations between baseline patient and disease characteristics, and longitudinal healthcare costs in Parkinson disease (PD). Background: Disease prevalence, disability-adjusted life-years, and PD…Path To Prevention (P2P) Therapeutics Platform Trial in Biomarker Defined Prodromal Parkinson’s Disease: Study Design
Objective: To describe the study design and proposed timeline of the first interventional study in biomarker defined prodromal Parkinson’s Disease (PD). Background: P2P is a…Validation and replication of Parkinson disease behavioral subtypes
Objective: To validate and replicate clinical subtypes of Parkinson disease. Background: We recently identified three distinct clinical subtypes of Parkinson disease: motor (predominant motor with…
- « Previous Page
- 1
- …
- 277
- 278
- 279
- 280
- 281
- …
- 436
- Next Page »